Lantheus to acquire Evergreen for $250m.

Lantheus, a radiopharmaceutical-focused company, agreed to acquire Evergreen, a company focused on improving the available options for cancer patients using radiopharmaceuticals, for $250m. “As Lantheus continues to advance its industry leadership, this transaction, along with the agreement to acquire Life Molecular Imaging, enhances our operations across the radiopharmaceutical value chain [...] With Evergreen’s manufacturing and development capabilities, we become fully integrated and will ultimately make a difference in the lives of more patients. We are pleased to welcome Evergreen’s talented team to Lantheus and are confident that their expertise in radiopharmaceutical theranostics and culture focused on developing new solutions for cancer patients will enrich our organization,” Brian Markison, Lantheus CEO.